Menopause hormone therapy not linked to premature death

(Reuters Health) - Women who take hormone replacement therapy (HRT) to ease menopause symptoms like hot flashes and night sweats may be no more likely to die prematurely than women who don ’t take hormones, a new study suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
THIS WEEK'S TOP STORIES Hormone therapy: Is it right for you??? Hormone replacement therapy ? medications containing female hormones to replace the ones the body no longer makes after menopause ? is sometimes used to treat common menopausal symptoms, including hot flashes and vaginal discomfort. Hormone therapy also has been proven to prevent bone loss [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Conclusions: Decisions regarding the use of HT in women who undergo BSO after detection of a BRCA mutation must be individualized based on careful consideration of the risks and benefits. However, the risks of a subsequent cancer diagnosis appear small, particularly in regards to the benefits of treatment afforded by HT.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
Publication date: February 2018 Source:Journal of Functional Foods, Volume 41 Author(s): Naice E.S. Monteiro, Lívia D. Queirós, Danielle B. Lopes, Adriana O. Pedro, Gabriela A. Macedo Menopause is a natural event that occurs in women around the age of 50 years, causing irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. Hormone replacement therapy has many benefits, but should be prescribed with caution in women with a history of stroke, thromboembolic events, certain types of cance...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Authors: Gambacciani M, Biglia N, Cagnacci A, DI Carlo C, Caruso S, Cicinelli E, DE Leo V, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A Abstract In the last decade the risk benefits ratio of HRT has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausel Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society,...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
CONCLUSION: Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism. PMID: 28969534 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
More News: Health | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Study | Women